Retrospective data analysis on sedation with esketamine during less invasive surfactant administration (LISA) in premature infants

Retrospective data analysis on sedation with esketamine during less invasive surfactant administration (LISA) in premature infants - Esketamine in LISA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036127

Enrollment

Registered

2025-02-07

Start date

2025-02-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

P22.0

Interventions

Group 1: Premature infants born in between March 1st, 2023 to December 31, 2024 with a gestational age of 22+0/7 - 37+0/7 weeks and in whom esketamine was administered as part of a LISA procedure.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Premature infants born in between March 1st, 2023 to December 31, 2024 with a gestational age of 22+0/7 - 37+0/7 weeks and in whom esketamine was administered as part of a LISA procedure.

Exclusion criteria

Exclusion criteria: Infants for whom the administration of the prescribed medication was not explicitly documented.

Design outcomes

Primary

Measure	Time frame
Percentage of LISA procedures documented as “complication-free” and “successfully completed”, without the occurrence of side effects/late effects	—

Secondary

Measure	Time frame
- Percentage of infants with adverse events/late effects (per laryngospasm, intubation during procedure, tachycardia, IVH, other) - Mean week of gestation at birth - Mean birth weight	—

Countries

Germany

Contacts

Public ContactChristian Maiwald

Universitätsklinikum Tübingen - Abteilung für Neonatologie

Christian.Maiwald@med.uni-tuebingen.de070712981418

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026